Arya Health

Arya Health continues its rapid growth trajectory, expanding its AI agent platform to new administrative functions and capturing significant market share in the underserved post-acute care sector. Strategic partnerships and further acquisitions, building on the HippoAI deal, accelerate product development and customer adoption. This leads to a valuation of approximately $292M (4x current valuation) within two years, providing substantial returns for common shareholders after accounting for liquidation preferences.

Arya Health maintains strong, albeit slightly moderated, growth by effectively competing against specialized players and carving out its niche. It successfully raises a Series B round, demonstrating continued product-market fit and customer retention. The company reaches a valuation of around $146M (2x current valuation) within two years, allowing for meaningful returns for common shareholders after the $25M liquidation preference is satisfied.

Despite initial high growth, Arya Health struggles to fend off larger incumbents like Epic or Cerner, or well-funded competitors like Infinitus, who expand their AI offerings into post-acute administrative automation. This leads to slower-than-expected growth, difficulty raising subsequent funding at a higher valuation, or a distressed acquisition. A valuation drop to $14.6M (an 80% decrease) would result in common stock being worthless due to the $25M in liquidation preferences held by investors.